The estimated Net Worth of Mangini Siobhan Nolan is at least $1.22 millió dollars as of 16 February 2020. Ms Nolan owns over 83,925 units of Ngm Biopharmaceuticals Inc stock worth over $729,675 and over the last 8 years she sold NGM stock worth over $131,848. In addition, she makes $355,445 as CFO and Principal Financial & Accounting Officer at Ngm Biopharmaceuticals Inc.
Ms has made over 35 trades of the Ngm Biopharmaceuticals Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently she exercised 83,925 units of NGM stock worth $129,245 on 16 February 2020.
The largest trade she's ever made was exercising 86,424 units of Ngm Biopharmaceuticals Inc stock on 16 November 2019 worth over $133,093. On average, Ms trades about 17,037 units every 28 days since 2016. As of 16 February 2020 she still owns at least 473,815 units of Ngm Biopharmaceuticals Inc stock.
You can see the complete history of Ms Nolan stock trades at the bottom of the page.
Siobhan Nolan Mangini is the CFO and Principal Financial & Accounting Officer at Ngm Biopharmaceuticals Inc.
As the CFO and Principal Financial & Accounting Officer of Ngm Biopharmaceuticals Inc, the total compensation of Ms Mangini at Ngm Biopharmaceuticals Inc is $355,445. There are 7 executives at Ngm Biopharmaceuticals Inc getting paid more, with David Woodhouse having the highest compensation of $2,092,150.
Ms Mangini is 40, she's been the CFO and Principal Financial & Accounting Officer of Ngm Biopharmaceuticals Inc since . There are 16 older and 1 younger executives at Ngm Biopharmaceuticals Inc. The oldest executive at Ngm Biopharmaceuticals Inc is David Goeddel, 68, who is the Lead independent director.
Mangini's mailing address filed with the SEC is C/O ALIGHT, INC., 4 OVERLOOK PT, LINCOLNSHIRE, IL, 60069.
Over the last 6 years, insiders at Ngm Biopharmaceuticals Inc have traded over $9,159,599 worth of Ngm Biopharmaceuticals Inc stock and bought 18,889,291 units worth $177,396,366 . The most active insiders traders include Peter Svennilson, David V Goeddel és Group L P Svennilson Peter .... On average, Ngm Biopharmaceuticals Inc executives and independent directors trade stock every 9 days with the average trade being worth of $171,092. The most recent stock trade was executed by Group L Ptcg Opportunity Ii... on 15 November 2023, trading 22,631 units of NGM stock currently worth $15,615.
ngm bio is a research-driven, clinical stage biopharmaceutical company with a drug discovery platform designed to generate a pipeline of first-in-class biologic drug candidates. our initial r&d focus has been on cardio-metabolic and liver disease, but we believe that our research expertise – comprehensive and grounded in fundamental, interrelated mechanisms of human biology – is capable of driving the development of new therapies for a wide range of disease areas such as cancer. ngm bio’s comprehensive approach to drug discovery focuses on elucidating the biology of hormones, cell receptors and associated ligands. as we investigate these novel biological mechanisms, we assemble a deep understanding of the relationship between the structure and function of proteins of interest. coupled with our experience in protein and antibody engineering, our approach enables the efficient and targeted generation of potential first-in-class therapeutics with optimized pharmacologic profiles. work
Ngm Biopharmaceuticals Inc executives and other stock owners filed with the SEC include: